Artwork

Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

01_09 Metastatic Cholangiocarcinoma

23:31
 
Del
 

Manage episode 334645960 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. Overview of nomenclature, etiology and presentation

2. Management of symptoms and prognosis

3. Systemic therapy in the first line

4. Second line and biomarker driven management

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Marabelle A et al.. J Clin Oncol. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

2. Lamarca A et al. The Lancet Oncology. 2021;22(5):690-701. doi:10.1016/S1470-2045

3. Zia MI, Siu LL, et al. Journal of Clinical Oncology. 2005;23(28):6982-6991. doi:10.1200/JCO.2005.06.679

4. Phelip JM et al. J Clin Oncol. 2022;40(3):262-271. doi:10.1200/JCO.21.00679

5. Valle J et al. NEJM. 2010;362(14):1273-1281. doi:10.1056/NEJMOA0908721

6. Oh DY et al. NEJM Evidence. Published online June 1, 2022. doi:https://doi.org/10.1056/EVIDoa2200015

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

  continue reading

49 episoder

Artwork
iconDel
 
Manage episode 334645960 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. Overview of nomenclature, etiology and presentation

2. Management of symptoms and prognosis

3. Systemic therapy in the first line

4. Second line and biomarker driven management

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Marabelle A et al.. J Clin Oncol. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

2. Lamarca A et al. The Lancet Oncology. 2021;22(5):690-701. doi:10.1016/S1470-2045

3. Zia MI, Siu LL, et al. Journal of Clinical Oncology. 2005;23(28):6982-6991. doi:10.1200/JCO.2005.06.679

4. Phelip JM et al. J Clin Oncol. 2022;40(3):262-271. doi:10.1200/JCO.21.00679

5. Valle J et al. NEJM. 2010;362(14):1273-1281. doi:10.1056/NEJMOA0908721

6. Oh DY et al. NEJM Evidence. Published online June 1, 2022. doi:https://doi.org/10.1056/EVIDoa2200015

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

  continue reading

49 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill